Formation Bio Expands Leadership Team with Industry Veterans

Sep 23, 2025
Formation Bio has announced the addition of four seasoned executives to its leadership team to enhance its AI-driven drug development efforts.

Formation Bio has announced the appointment of four experienced executives to its leadership team to bolster its AI-driven drug development initiatives, announced in a press release. The new appointees include Louis Brenner, MD, as Chief Medical Officer; Daniel Neil, PhD, as Chief Technology Officer; and Frank D'Amelio and Dashyant Dhanak, PhD, as Senior Advisors.

Louis Brenner, MD, brings over 20 years of experience in biotech and pharma, having previously served as President and CEO of Hopewell Therapeutics. Daniel Neil, PhD, joins as Chief Technology Officer with a strong background in machine learning and AI, having led AI/ML strategies at Tessera Therapeutics and BenevolentAI.

Frank D'Amelio, with nearly 15 years as Chief Financial Officer at Pfizer, joins as a Strategic Advisor. Dashyant Dhanak, PhD, who has held senior roles at Incyte and BenevolentAI, will also serve as a Strategic Advisor. These appointments aim to strengthen Formation Bio's capabilities in clinical, technological, financial, and scientific domains as it scales its AI-native pharma model.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.